In vitro activity of the new quinoline derivative ciprofloxacin alone and in combination against various Mycobacterium-, Salmonella- and Escherichia coli strains
Rosenfeld, M.; Spannuth, G.; Wempe, E.; Kunz, B.; Bartels, H.; Visser, K.; Seydel, J.K.; Ruschmeyer, H.J.
Arzneimittel-Forschung 36(6): 904-912
1986
ISSN/ISBN: 0004-4172 PMID: 2943293 Document Number: 278198
The antibacterial effect of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazine-1-ylquinoline++ + 3-carboxylic acid (ciprofloxacin, Bay o 9867) has been tested using different test systems and various strains, especially of Escherichia coli, Mycobacterium and Salmonella. Ciprofloxacin shows low MIC's against most of the tested strains. The high in vitro and in vivo activity against Salmonella is most promising for cure of salmonellosis.